These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Transient cefuroxime/metronidazole treatment induced factor V antibodies. Van den Berg SA; Verwer PE; Idema RN; Van Guldener C BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25139922 [TBL] [Abstract][Full Text] [Related]
24. Life-threatening bleeding tendency provoked by an acquired isolated factor X deficiency associated with respiratory infection. Coucke L; Trenson S; Deeren D; Van haute I; Devreese K Ann Hematol; 2013 Oct; 92(10):1437-8. PubMed ID: 23463452 [No Abstract] [Full Text] [Related]
25. And the question is...Is the patient bleeding or clotting? A guide to appropriate testing and evaluation. Miller-Canfield PA W V Med J; 2007; 103(4):13. PubMed ID: 18159837 [TBL] [Abstract][Full Text] [Related]
26. [Changes in the blood coagulation system in patients with hypo- and aplastic anemia]. Klimova KN; Alekseev NA; Abdulkadyrov KM; Beznosikov BO Probl Gematol Pereliv Krovi; 1966 Jun; 11(6):27-34. PubMed ID: 5990676 [No Abstract] [Full Text] [Related]
27. [Acquired inhibitor of factor V: an uncommon cause of prolonged coagulation tests]. Hernández JA; Alonso A; Bermejo A; Velayos C Med Clin (Barc); 2006 Mar; 126(9):359. PubMed ID: 16650377 [No Abstract] [Full Text] [Related]
28. Acquired factor V inhibitor in a patient with acquired human immunodeficiency syndrome. Brickner LA; Scannell KA; Sahud MA Am J Hematol; 1996 Aug; 52(4):332-3. PubMed ID: 8701963 [No Abstract] [Full Text] [Related]
29. [Hematopoietic organ and bleeding tendency]. Terada H Nihon Rinsho; 1991 Apr; 49(4):859-64. PubMed ID: 2072544 [No Abstract] [Full Text] [Related]
30. Hyperviscosity syndrome in patients with multiple myeloma. Mullen E; Mendez N Oncol Nurs Forum; 2008 May; 35(3):350-2. PubMed ID: 18467286 [No Abstract] [Full Text] [Related]
31. A circulating factor V inhibitor: possible side effect of treatment with streptomycin. Stenbjerg S; Husted S; Mygind K Scand J Haematol; 1975 May; 14(4):280-5. PubMed ID: 1153957 [TBL] [Abstract][Full Text] [Related]
34. Acquired factor V inhibitor in a critically ill patient. Morris CJ; Curry N Anaesthesia; 2009 Sep; 64(9):1014-7. PubMed ID: 19686488 [TBL] [Abstract][Full Text] [Related]
35. Hemorrhagic death associated with a high titer factor V inhibitor. Coots MC; Muhleman AF; Glueck HI Am J Hematol; 1978; 4(2):193-206. PubMed ID: 677121 [TBL] [Abstract][Full Text] [Related]
36. Bleeding issues in neonates, infants and young children. Kenet G; Krümpel A; Nowak-Göttl U Thromb Res; 2009; 123 Suppl 2():S35-7. PubMed ID: 19217472 [No Abstract] [Full Text] [Related]
37. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. Franchini M; Sassi M; Dell'Anna P; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Targher G; Lippi G Semin Thromb Hemost; 2009 Feb; 35(1):76-80. PubMed ID: 19308895 [TBL] [Abstract][Full Text] [Related]
39. Factor V Leiden thrombophilia: presentation of three patients and a literature review. Cruz-Amy M; Hunter-Mellado R Bol Asoc Med P R; 2006; 98(3):213-21. PubMed ID: 19610561 [TBL] [Abstract][Full Text] [Related]